Skip to main content
. 2023 Jan 17;15(3):562. doi: 10.3390/cancers15030562

Figure 2.

Figure 2

De novo lipid biosynthesis makes CRC cell lines more resistant to oxaliplatin. (A) Intracellular neutral lipid droplets and triglycerides were decreased in oxaliplatin-resistant cells after FASN knockdown. The storage of lipids is shown as bodipy 493/503 staining of neutral lipid droplets. (B) Upon treatment with same dose of oxaliplatin, there was a significant fold decrease in proliferation in the FASN knockdown CRC cells. (C) Transwell assay indicated that FASN knockdown inhibited migration of oxaliplatin-resistant CRC cells previously treated with 20 μM oxaliplatin for 72 h. (D) FASN knockdown and relative wild-type oxaliplatin-resistant CRC cells were previously treated with 20 μM oxaliplatin for 72 h. Clonogenic assay was performed as 500 cells seeded in 6-well plates for 7 days and counting. (E,F) Intracellular neutral lipid droplets, triglycerides, and IC50 of oxaliplatin increased after FASN overexpression. (G) Transwell assay indicated that FASN overexpression improved migration of CRC cells previously treated with 5 μM oxaliplatin for 72 h. (H) There was a distinct increase in colony formation in FASN-overexpression CRC cells. * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001.